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Description of the technology
Protein microarrays are used to identify targets of
drugs, small molecules, and enzyme substrates that
may be modified in numerous ways such as by
phosphorylation or methylation, to detect protein binding
properties, investigate protein-protein interactions, and to
define protein-based biomarkers in a high-throughput
manner. They are based on the development of DNA
microarray techniques and have thousands of purified
proteins immobilized on a solid surface. The technique
requires a blocking step to be applied to remove any
non-specific binding. After incubation of the protein
probe (e.g. patient serum) with a suitable tag, visible
detection reagents are employed to quantify the cor-
responding signals. Proteins microarray are classified
into three types: analytical, functional and reverse-phase
protein microarrays [1]. Functional protein microarrays
are widely used because of their commercial availability.
As an example, ProtoArray® offers a unique approach to
analyze the serological response against thousands of pro-
teins (~9000) simultaneously. ProtoArray® does not cover
the entire proteome, but a serological analysis of clinical
samples using this protein microarray allows high-content
"seromics” screening against a substantial portion of the
human proteome to identify potential antibody bio-
markers and reactivity patterns that may correlate with
disease state or treatment response.
A new, emerging protein array that utilizes molecular
technology for the detection of protein abundance in
serum, other body fluids and cell lysates. This technol-
ogy is represented by SomaLogic's SOMAmer® (Slow
Off-rate Modified Aptamer) proteomic assay. This
technology combines the properties of antibodies and
traditional aptamers with extremely large specificity
assembly. The selected target specific aptamers with
specific three-dimensional structure are modified into
a “SOMAmer” that provides protein-binding specifi-
city as well as the primary nucleic acid sequence
backbones with streptavidin linker attached to beads
bind to proteins in the sample mix. The proteins that
are bound to their specific SOMAmer reagents are
then biotinylated followed by photocleaving of the
linker to release the SOMAmer-protein complexes.
Via subsequent capture, all biotinylated proteins are
bound to a second streptavidin bead followed by
denature of SOMAmer-protein targets, protein tar-
geted SOMAmer are collected, labeled, denatured and
hybridized to DNA array fabricated by the complementary
strand of the SOMAmers. This technology can efficiently,
accurately and rapidly identify and quantify over 1000
proteins across approximately eight logs of concentration
in small sample volumes. Other protein microarrays are
under research level development and not yet widely
applied for immune monitoring.
Here, we concentrate on the ‘seromics’ ProtoArray®
technology for the following discussion regarding
samples and data in detail. The workflow of an example
protein microarray is illustrated in Fig. 1, showing the ap-
proach for detecting an antibody response in peripheral
blood by this platform [2, 3].
Type of data obtained/readout
Similar to DNA microarrays, a potentially large num-
ber of fluorescence signals may be obtained from
each array depending on the amount and diversity of
antibodies or proteins in each sample that may bind
to the thousands of proteins coated on each slide.
The results of positive controls are used to determine
the quality of the assay. A microarray scanner is
required to read and quantitate the fluorescence units
from each slide, and results can be exported into
spreadsheet format. Bioinformatics is essential to
handling and processing the large amount of data
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obtained through multiple steps including data acquisition,
pre-processing, visualization, differential analysis, result
verification and computational feature annotation and net-
work analysis. Several software and computational tools
have been developed for signal detection, data preprocess-
ing, quality control and data normalization [4–6].
Limitations of the approach
Different proteins may be coated at different amounts
on the slides resulting in potentially different levels of
fluorescence signal; therefore the assay is not meant to
be quantitative when comparing results between the
various proteins. As may be expected from high content
analyses, there are also potential non-specific, false posi-
tive events that can be found from protein microarray
analysis. Therefore, it is critical that the identified anti-
bodies/antigens should be validated by other assays such
as western blot, ELISA, Luminex or mass spectrometry.
Given the large scale of protein synthesis required for
manufacture of the arrays and the ability to run only 1
sample per slide, the assay is relatively expensive which
needs to be overcome for more widespread application
and use in larger scale clinical trials. The somewhat
limited number of proteins coated on the slides (e.g. not
all human proteins are present and mutated or modified
versions of proteins may not be available), and lack of
availability of antibodies in other complimentary plat-
forms to verify specificity of each of the proteins on the
slides also currently restricts the broader application of
the analytical protein microarray platform.
Types of samples needed and special issues pertaining to
samples
Proper collection and storage of samples and careful
standardized sample processing procedure are required
to minimize inter- and intra-assay variation and im-
prove the data reproducibility. Frozen serum and
plasma samples collected from blood are usually kept
in −20 or −80 °C freezer for long-term storage to pre-
serve sample stability. Batched pre- and post-therapy
sample analyses performed in a single run are recom-
mended to avoid possible differences arising from the
inter-assay variation. Samples should not be subjected
to multiple freeze-thaw cycles in order to minimize po-
tential degradation of proteins in the sample as well.
Special attention should be given to therapeutic agents
that may be present in samples as a result of patient
Fig. 1 Workflow of protein microarray development for the antibody response biomarker profiling. Step 1: Incubate the slides with blocking
buffer to reduce non-specific background, then add diluted serum/plasma samples for two hours’ incubation. Step 2: Wash the slides with probing/
washing buffer, then incubate fluorescence conjugated anti-human IgG antibody for another two hours. Step 3: Wash slides with probing buffer and
deionized water, and dry the slides with centrifugation. After drying, immediately transfer the arrays to a slide carrier of the GenePix 4200AL fluorescent
microarray scanner. Step 4: Scan the array, and analyze the data in GenePix Pro 6.1 software or export the results for additional analysis
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drug therapy which may interfere with interpretation of
results due to interactions with proteins in the arrays.
Level of evidence
The sensitivity and specificity of a protein microarray were
compared to the standard ELISA with a 94 % concordance
[2, 3]. Specific autoantibody responses have been associ-
ated with tumor progression for patients with a wide
range of cancers [7–9]. Humoral antigen spreading re-
sponse induced by Sipuleucel-T therapy has been shown
to be associated with improved overall survival [10]. Cyto-
toxic T lymphocyte antigen-4 (CTLA-4) blockade was
showed to induce a larger number of antibody responses
in the clinical responders than non-responders in patients
with prostate cancer [6]. It was also shown that a prostate
cancer patient with a sustained complete response to
CTLA-4 blockade mounted a strong humoral response
against a small number of proteins [11]. A major question
for this technology is whether the development of IgG
antibody responses, which require CD4 T cell help for Ig
class-switching, can serve as a surrogate for T cell immun-
ity [4]. More than 150 papers have been published using
this ProtoArray® platform in last ten years. Further
research is warranted to validate this novel technology
and these potential biomarkers sufficiently in the clinical
setting for routine clinical application.
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